Posts by Mourabit Halima

In recent years, rapid advances in surgical robotics and information technology have enabled remote robotic surgery to transcend geographic barriers and redefine the future of surgical care. At the same time, China’s innovative drug development efforts have achieved major international milestones. The phase III RC48-C016 study evaluating toripalimab plus disitamab vedotin (DV) as first-line treatment for urothelial carcinoma was published in The New England Journal of Medicine (NEJM), marking a landmark achievement for Chinese oncology research.

Urothelial carcinoma is one of the most common malignancies of the urinary tract, with bladder cancer representing its most prevalent subtype. In recent years, immunotherapy has offered new hope for patients with advanced disease. However, not all patients derive meaningful benefit.

Upper tract urothelial carcinoma (UTUC) accounts for a substantially higher proportion of urothelial carcinoma cases in China than in Western populations. Although radical nephroureterectomy remains the standard treatment for UTUC, many patients become ineligible for cisplatin-based chemotherapy after surgery because of impaired renal function and other comorbidities. Furthermore, subgroup analyses from three major adjuvant immunotherapy trials have failed to demonstrate a significant disease-free survival (DFS) benefit in patients with UTUC, underscoring the urgent need for novel therapeutic strategies.

For nearly four decades, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma (UC). However, its limitations—including modest survival outcomes and significant treatment-related toxicity—have persisted as major clinical challenges.